Wyeth collaboration boosts Ablynx's prospects
This article was originally published in Scrip
Executive Summary
Ablynx's development partner Wyeth may initiate a Phase II proof-of-concept study for an anti-TNF alpha Nanobody, potentially becoming Ablynx's first partnered product to enter Phase II, analysts say.